Ten Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2018

In this online program, faculty discuss how to leverage 10 of the emerging and most clinically important biomarkers to optimize patient care across multiple tumor types, from solid tumors to hematologic malignancies.

Learn about biomarkers agnostic to tumor type as well as an in-depth look at case studies in non-small-cell lung cancer, acute myeloid leukemia, and chronic lymphocytic leukemia for examples of personalized medicine in 2018.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD
Hagop M. Kantarjian, MD
Edward S. Kim, MD, FACP
John L. Marshall, MD
Andrew D. Zelenetz, MD, PhD

On-Demand Webcast

Watch this CME/CE-certified Webcast of a dynamic CCO symposium at ASCO 2018 to review the ten most clinically relevant biomarkers in oncology with program chair John L. Marshall, MD, and experts Todd M. Bauer, MD; Hagop M. Kantarjian, MD; Edward S. Kim, MD, FACP; and Andrew D. Zelenetz, MD, PhD.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: July 10, 2018 Expiration: July 9, 2019

Downloadable Slidesets

In this downloadable slideset, John L. Marshall, MD, examines key oncology biomarkers for immune checkpoint inhibition and DNA repair, MSI/MMR, PD-L1, and BRCA1/2.

John L. Marshall, MD Released: June 4, 2018

In this downloadable slideset, Todd M. Bauer, MD, discusses the rationale for targeting tumor agnostic genetic aberrations in patients with cancer, including FGFR, RET, and TRK.

Todd M. Bauer, MD Released: June 4, 2018

In this downloadable slideset, Edward S. Kim, MD, FACP, explains how various biomarkers can be used to guide treatment of patients with lung cancer, including EGFR, ALK, ROS-1, BRAF, and PD-L1.

Edward S. Kim, MD, FACP Released: June 8, 2018

In this downloadable slideset, Hagop M. Kantarjian, MD, discusses the use of biomarkers to guide treatment of patients with acute myeloid leukemia, including IDH, FLT3, and CD33/CD133.

Hagop M. Kantarjian, MD Released: June 4, 2018

In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, examines and discusses the use of del(17p)/TP53 mutations to guide treatment of patients with chronic lymphocytic leukemia.

Andrew D. Zelenetz, MD, PhD Released: June 5, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
Agios Pharmaceuticals
Bayer Healthcare Pharmaceuticals Inc.
Celgene Corporation
Foundation Medicine, Inc.
Loxo Oncology
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?